18 Mar 2012 Calon Cardio-Technology appoints Simon Cartmell

Calon, the innovative LVAD company, today announces the appointment of Simon Cartmell as Chief Executive Officer.

Prof Marc Clement, Chairman, said "we are delighted that Simon has joined Calon to lead us through the next stage of our development. As a seasoned medical technology entrepreneur with a proven record of building start up UK companies to become successful global leaders in their field and delivering tremendous value for shareholders, Simon brings a wealth of relevant experience to Calon as it embarks on taking its novel LVAD technology into pivotal studies this year".

Simon Cartmell joins Calon after driving the development of ApaTech, a world leading bone grafting from 2003 until its sale to Baxter International Inc in March 2010 for $330m. He commented "since leaving ApaTech I have been seeking a similar opportunity - an early stage UK company with really exciting technology that, if developed properly and funded well, will be able to bring significant benefits to patients and the healthcare providers and payers who support them. I believe in Calon I have found such a company."

Calon has recently completed a Series B fundraising backed by Finance Wales and Longbow and has relocated to the state of the art Institute of Life Sciences, part of the College of Medicine on Swansea University.

For more information, contact Prof Marc Clement, Chairman, Calon Cardio-Technology, on 01792 602811



Disclaimer: Calon Cardio’s VAD devices are not available for sale, including in the United States of America